BEIJING — China conditionally approved the registration application of a self-developed recombinant protein subunit vaccine against COVID-19, the National Medical Products Administration said on March 2.

The vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical Co Ltd, was allowed to enter the market on a conditional basis, said the administration.

It marked the first approved COVID-19 recombinant protein subunit vaccine in China.